Publication

Model-based analysis of treatment effects of paclitaxel microspheres in a microscopic peritoneal carcinomatosis model in mice

Xie, F., De Clercq, K., Vervaet, C., Van Bocxlaer, J., Colin, P. & Vermeulen, A., Sep-2019, In : Pharmaceutical Research. 36, 9, 13 p., 127.

Research output: Contribution to journalArticleAcademicpeer-review

Copy link to clipboard

Documents

  • Model-based analysis of treatment effects of paclitaxel microspheres in a microscopic peritoneal carcinomatosis model in mice

    Final publisher's version, 1 MB, PDF-document

    Request copy

DOI

  • Feifan Xie
  • Kaat De Clercq
  • Chris Vervaet
  • Jan Van Bocxlaer
  • Pieter Colin
  • An Vermeulen

PurposePaclitaxel (PTX)-loaded genipin-crosslinked gelatin microspheres (GP-MS) are a prolonged IP delivery system under development for the treatment of peritoneal minimal residual disease (pMRD). Here, we show the use of a pharmacokinetic-pharmacodynamic (PKPD) modelling approach to inform the formulation development of PTX-GP-MS in a mice pMRD model.MethodsPTX blood concentrations and survival data were obtained in Balb/c Nu mice receiving different single IP doses (7.5 and/or 35 mg/kg) of PTX-ethanolic loaded GP-MS (PTXEtOH-GP-MS), PTX-nanosuspension loaded GP-MS (PTXnano-GP-MS), and immediate release formulation Abraxane (R). A population PK model was developed to characterize the PTX blood concentration pattern and to predict PTX concentrations in peritoneum. Afterwards, PKPD relationships between the predicted peritoneal or blood concentrations and survival were explored using time-to-event modelling.ResultsA PKPD model was developed that simultaneously describes the competing effects of treatment efficacy (driven by peritoneal concentration) and toxicity (driven by blood concentration) of PTX on survival. Clear survival advantages of PTXnano-GP-MS over PTXEtOH-GP-MS and Abraxane (R) were found. Simulations of different doses of PTXnano-GP-MS demonstrated that drug-induced toxicity is high at doses between 20 and 35 mg/kg.ConclusionsThe model predicts that the dose range of 7.5-15 mg/kg of PTXnano-GP-MS provides an optimal balance between efficacy and safety.

Original languageEnglish
Article number127
Number of pages13
JournalPharmaceutical Research
Volume36
Issue number9
Publication statusPublished - Sep-2019

    Keywords

  • Mouse, NONMEM, Paclitaxel, Peritoneal, PKPD, HYPERTHERMIC INTRAPERITONEAL CHEMOTHERAPY, GYNECOLOGIC-ONCOLOGY-GROUP, OVARIAN-CANCER, STAGE-III, IN-VITRO, CYTOREDUCTIVE SURGERY, CISPLATIN, VIVO, RATIONALE, STANDARD

View graph of relations

ID: 90740600